Danuglipron
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Danuglipron
- Molecular weight
- 555.61
- Structure (SMILES)
- N#Cc1ccc(COc2cccc(C3CCN(Cc4nc5ccc(C(=O)O)cc5n4C[C@@H]4CCO4)CC3)n2)c(F)c1
- 2 4 6 4 cyano 2 fluorobenzyl oxy pyridin 2 yl piperidin 1 yl methyl 1 2s oxetan 2 ylmethyl 1h benzimidazole 6 carboxylic acid
- 2-((4-(6-((4-CYANO-2-FLUOROBENZYL)OXY)PYRIDIN-2-YL)PIPERIDIN-1-YL)METHYL)-1-((2S)-OXETAN-2- YLMETHYL)-1H-BENZIMIDAZOLE-6-CARBOXYLIC ACID
- danuglipron
- Danuglipron
- danuglipron [INN]
- DANUGLIPRON [USAN]
- Danuglipron [WHO-DD]
- danuglipron inn
- danuglipron usan
- danuglipron who dd
- pf 06882961
- Pf-06882961
- PF-06882961
- PF-06882961 (Cohort 3)
- PF-06882961 100 mg
- PF-06882961 20 mg
- PF-06882961 20MG
- PF-06882961 Immediate Release Solution
- PF-06882961 Immediate Release Tablet
- CAS registry numbers
- 2230198-02-2
- ChEMBL ID
- CHEMBL4518483
- InChIKey
- HYBAKUMPISVZQP-DEOSSOPVSA-N
- PubChem compound IDs
- 134611040
- FDA ingredient codes (UNII)
- DN9IUI24GP
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- danuglipron
- Type
- Synthetic organic
- Drug name stem
- -glipron
- Action
- Agonist
- Action type
- Agonist
- Target
- GLP-1 receptor
- Gene symbol
- GLP1R
- Protein identifier
- P43220
- Median affinity
- 7.63
- Affinity units
- pEC50
- Mechanism
- Glucagon-like peptide 1 receptor agonist
- Action type
- Agonist
- Target
- Glucagon-like peptide 1 receptor
- Protein identifier
- P43220
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Kv11.1
- Gene symbol
- KCNH2
- Protein identifier
- Q12809
- Median affinity
- 5.03
- Affinity units
- pIC50
Open Targets mechanisms
- Mechanism
- Glucagon-like peptide 1 receptor agonist
- Action type
- Agonist
- Target
- Glucagon-like peptide 1 receptor
- Condition
- Obesity
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Non-alcoholic Fatty Liver Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003095
- Subject identifier
- D065626
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition identifier
- EFO_0001073
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003095
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0011122
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0013209
- NCT03538743
- NCT03985293
- NCT04552470
- NCT04889157
- NCT04604496
- NCT04616339
- NCT04621227
- NCT04707313
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 1
- Polar surface area
- 113.5
- Calculated partition coefficient (ALogP)
- 4.89
- Calculated partition coefficient (XLogP)
- 1.4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 9
- Heavy atoms
- 41
- Molecular formula
- C31H30FN5O4
- Monoisotopic mass
- 555.22818262
- Natural product
- No
- Recorded assays
- 181
- Active assays
- 48
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (62)
- 4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
- A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
- A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
- A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects
- A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation
- A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy
- A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.
- A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961
- A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism
- A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
- A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis
- A Study of AV0328 Administered to Healthy Adult Volunteers
- A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)
- A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma
- A Study of M701 (EpCAM and CD3) in Malignant Ascites
- A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors
- A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus
- A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants
In development for (4)
- Liver disorder Phase 1
- Metabolic dysfunction-associated steatotic liver disease Phase 1
- Obesity disorder Phase 2
- Type 2 diabetes mellitus Phase 2
Targets (1)
- GLP1R Glucagon-like peptide 1 receptor agonist